S

Systimmune

Develops bispecific antibodies and ADCs

Biostatistician

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timePrinceton, NJ, USA$80k - $140k /yrIn-person

About the Job

Requirements

  • A PhD in Biostatistics, Statistics, or a related quantitative field.
  • At least 1 year of industry experience in biostatistics within a pharmaceutical, biotechnology, or contract research organization setting.
  • Hands-on experience supporting clinical trials in any phase.
  • Proficiency in statistical programming using R and/or SAS.
  • Understanding of clinical trial design, endpoints, and regulatory expectations.
  • Bilingual proficiency in Mandarin and English.

Responsibilities

  • Support statistical activities for clinical trials across Phase 1 to Phase 3 studies.
  • Develop statistical analysis plans.
  • Contribute to study design, including sample size estimation and statistical methodology.
  • Collaborate with clinical, data management, and programming teams to ensure data integrity and analysis accuracy.
  • Work with global teams, including close collaboration with colleagues in China.
  • Assist in interpreting statistical results and communicate findings clearly to cross-functional stakeholders.

About the Company

Systimmune

Develops bispecific antibodies and ADCs

Systimmune is a biopharmaceutical company that develops antibody-based cancer therapies, including bispecific and trispecific antibodies and antibody-drug conjugates (ADCs). These products are designed to act on the solid tumor micro-environment to directly attack tumors and/or to activate the immune system to fight cancer. The company uses multiple immuno-oncology platforms and experienced scientists to create biologics that intervene in the tumor environment in systematic ways. Compared with competitors, Systimmune emphasizes integrating several antibody-based modalities (bispecifics, trispecifics, and ADCs) and a deep focus on the solid tumor micro-environment, aiming to translate biological insight into targeted, immune-engaging therapies. The goal is to produce biologics that effectively modulate the tumor environment and mobilize the body's own immune response to destroy cancer cells.

Company size
11-50
Company stage
Not listed
Total funding
Not listed
Headquarters
Redmond, WA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Systimmune

See more jobs